May 28 (Reuters) - Johnson & Johnson ( JNJ ):
* NUMAB THERAPEUTICS ANNOUNCES JOHNSON & JOHNSON TO ACQUIRE
ITS
WHOLLY-OWNED SUBSIDIARY YELLOW JERSEY THERAPEUTICS INCLUDING
RIGHTS TO NM26, A BI-SPECIFIC ANTIBODY FOR THE TREATMENT OF
ATOPIC DERMATITIS
Source text for Eikon:
Further company coverage: